KR101589464B1 - New bifidobacterium strain and nutraceutical composition for improving growth comprising the same - Google Patents
New bifidobacterium strain and nutraceutical composition for improving growth comprising the same Download PDFInfo
- Publication number
- KR101589464B1 KR101589464B1 KR1020150071119A KR20150071119A KR101589464B1 KR 101589464 B1 KR101589464 B1 KR 101589464B1 KR 1020150071119 A KR1020150071119 A KR 1020150071119A KR 20150071119 A KR20150071119 A KR 20150071119A KR 101589464 B1 KR101589464 B1 KR 101589464B1
- Authority
- KR
- South Korea
- Prior art keywords
- bifidobacterium
- cbt
- strain
- kctc
- food composition
- Prior art date
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000002417 nutraceutical Substances 0.000 title abstract description 3
- 235000021436 nutraceutical agent Nutrition 0.000 title abstract description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 52
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 30
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 30
- 235000020256 human milk Nutrition 0.000 claims abstract description 15
- 210000004251 human milk Anatomy 0.000 claims abstract description 14
- 230000029087 digestion Effects 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 230000001737 promoting effect Effects 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 239000004202 carbamide Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 241001608472 Bifidobacterium longum Species 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 108010046334 Urease Proteins 0.000 claims description 5
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 5
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 5
- 229940014144 folate Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 4
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 4
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 claims description 3
- 208000001613 Gambling Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 235000020299 breve Nutrition 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 230000001133 acceleration Effects 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 14
- 229940039696 lactobacillus Drugs 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108060006633 protein kinase Proteins 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 229940004120 bifidobacterium infantis Drugs 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229960002227 clindamycin Drugs 0.000 description 5
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- 235000021391 short chain fatty acids Nutrition 0.000 description 5
- 108010062877 Bacteriocins Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940050410 gluconate Drugs 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229930001119 polyketide Natural products 0.000 description 4
- 229930001118 polyketide hybrid Natural products 0.000 description 4
- 125000003308 polyketide hybrid group Chemical group 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100035149 Cytosolic endo-beta-N-acetylglucosaminidase Human genes 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 101710144190 Endo-beta-N-acetylglucosaminidase Proteins 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102100032487 Beta-mannosidase Human genes 0.000 description 2
- 241000131482 Bifidobacterium sp. Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 238000004977 Hueckel calculation Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 101150057615 Syn gene Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 108010055059 beta-Mannosidase Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- -1 hydroxypropyl ethyl Chemical group 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003881 polyketide derivatives Chemical class 0.000 description 2
- 125000000830 polyketide group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 230000019702 secondary metabolite biosynthetic process Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AVPDLWTUGIZJLH-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C([O-])=O.C[NH+](C)CCOC(=O)C(C)=C AVPDLWTUGIZJLH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NNDHDYDFEDRMGH-CAEIVAEBSA-N Anthranoyllycoctonine Chemical compound C([C@]12CN(C3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N NNDHDYDFEDRMGH-CAEIVAEBSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 101100427860 Brucella suis biovar 1 (strain 1330) ureE1 gene Proteins 0.000 description 1
- QUNSSAMCQPCOKJ-UHFFFAOYSA-N C[N+](C)(C)Cl.CCOC(=O)C=C.COC(=O)C(C)=C.CCOC(=O)C(C)=C Chemical compound C[N+](C)(C)Cl.CCOC(=O)C=C.COC(=O)C(C)=C.CCOC(=O)C(C)=C QUNSSAMCQPCOKJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101100021923 Helicobacter pylori (strain ATCC 700392 / 26695) lspA gene Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- UXOXDDUEWZOAIW-UHFFFAOYSA-N Inuline Natural products CCN1CC2(CC(=O)Oc3ccccc3N)CCC(OC)C45C6CC7C(CC(O)(C6C7OC)C(O)(C(OC)C24)C15)OC UXOXDDUEWZOAIW-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000970807 Thermoanaerobacterales Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710131072 Urease subunit alpha Proteins 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VNRZCPPHNPEBFC-UHFFFAOYSA-N anthranoyllycoctonine Natural products CCN1CC2(COC(=O)c3ccccc3N)CCC(OC)C45C2C(OC)C(O)(C14)C6(O)CC(OC)C7CC5(O)C6C7OC VNRZCPPHNPEBFC-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DLRVVLDZNNYCBX-LIZSDCNHSA-N beta-D-Glcp-(1->6)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-LIZSDCNHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 101150073660 glmM gene Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009578 growth hormone therapy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- SUSRLLXAXAIZPH-OBPIAQAESA-N hydroquinone beta-D-glucopyranoside Natural products OC[C@H]1O[C@@H](Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O SUSRLLXAXAIZPH-OBPIAQAESA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- CJRQAPHWCGEATR-UHFFFAOYSA-N n-methyl-n-prop-2-ynylbutan-2-amine Chemical compound CCC(C)N(C)CC#C CJRQAPHWCGEATR-UHFFFAOYSA-N 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 101150030895 ureAB gene Proteins 0.000 description 1
- 101150014144 ureC gene Proteins 0.000 description 1
- 101150070667 ureD gene Proteins 0.000 description 1
- 101150008224 ureE gene Proteins 0.000 description 1
- 101150109657 ureF gene Proteins 0.000 description 1
- 101150046666 ureG gene Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A23L1/3014—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A23Y2300/55—
Abstract
Description
본 발명은 신규한 비피더스 균주 및 그를 함유하는 성장촉진용 기능성 식품 조성물에 관한 것으로, 더욱 상세하게는 모유 올리고당 대사 관련 유전자 및 비타민 생합성 유전자를 보유하여 성장 촉진 효과를 갖는 신규한 비피더스 균주 및 이를 포함하는 성장촉진용 조성물에 관한 것이다.The present invention relates to a novel bifidus strain and a functional food composition for growth promotion containing the same, and more particularly, to a novel bifidus strain having a mammalian oligosaccharide metabolism-related gene and a vitamin biosynthesis gene and having a growth promoting effect, And a composition for promoting growth.
사람의 성장은 대부분 성장판이 열려 있는 사춘기까지의 시기에 일어난다. 성장을 의학적으로 정의하면, 성숙에 수반되는 크기의 변화라고 할 수 있으며, 특히 소아의 성장이라 함은 신장의 증가뿐만 아니라 신체의 각 기관의 크기와 기능의 증대를 포괄적으로 포함하는 개념이다. Human growth usually occurs during puberty, when growth plates are open. Growth is defined as a change in size accompanied by maturation. In particular, pediatric growth is a concept that encompasses not only an increase in kidney but also an increase in the size and function of the organs of the body.
일반적으로 사람의 성장은 유전적 영향이 가장 크게 영향을 미치는 것으로 인식되고 있지만, 실제로는 유전적인 영향은 23% 정도 밖에 해당되지 않으며, 나머지 77%는 후천적 영향에 의해 결정된다. 최근 지속적인 경제 성장과 식습관의 서구화, 영양상태의 개선 등으로 인해 소아 및 청소년의 성장발육이 크게 증가되는 추세이다. 또한 외모와 큰 키를 선호하는 사회적 분위기가 고조됨에 따라서 성장에 대한 관심이 증대되고 있다. Generally, human growth is perceived as having the greatest impact on genetic impact, but in reality genetic impact is only about 23%, and the remaining 77% is determined by acquired effects. In recent years, growth and development of children and adolescents are increasing due to continuous economic growth, westernization of eating habits, and improvement of nutritional status. In addition, as the social atmosphere favoring appearance and big tall is increasing, interest in growth is increasing.
지금까지 알려진 성장을 촉진하기 위한 방법으로는 성장 호르몬 제제 투여 요법이 있다. 그러나 성장 호르몬 사용 시, 비용 부담이 클 뿐만 아니라 주사부위의 소양감, 발작, 지방위축과 고혈압, 당 불내성(glucose intolerance), 췌장염, 전신 알레르기 반응, 성장 호르몬 항체 양성, 암 발생 및 남성에게 여성화 유방 등의 증상과 같은 부작용이 있을 수 있다. 따라서 성장에 근본적으로 도움을 줄 수 있는, 안전하고 효과적인 식품 소재에 대한 개발이 절실히 필요한 실정이다.To date, known methods of promoting growth include growth hormone therapy. However, the use of growth hormone is not only costly, but also has the potential to reduce the risk of cannulation, seizures, fat atrophy and hypertension, glucose intolerance, pancreatitis, systemic allergic reaction, growth hormone antibody positive, There may be side effects such as the symptoms of. Therefore, there is an urgent need to develop safe and effective food materials that can fundamentally help growth.
국내 특허 제0887377호(유아 및 청소년을 위한 건강보조식품), 국내 특허 제10530211호(학습능력을 향상시키는 건강기능식품 조성물 및 그 제조방법), 국내 특허 제0561286호(건조효모, 천연물 추출분말 및 영양성분 혼합분말을 함유하여 성장발육에 도움을 주는 건강기능성 조성물) 등이 이러한 성장촉진용 식품을 제안하고 있으나, 이들은 성장 촉진 효과가 부족한 한계가 있다. Korean Patent No. 0887377 (health supplements for infants and young people), Korean Patent No. 10530211 (composition for health functional food for improving learning ability and method for producing the same), domestic patent No. 0561286 (dry yeast, A health functional composition containing a nutrient component mixed powder and supporting growth and development) have proposed such a food for growth promotion, but these have a limitation in that the growth promoting effect is insufficient.
본 발명은 상술한 종래 기술의 문제점을 해소하기 위한 것으로, 본 발명의 하나의 목적은 신생아, 영유아, 소아 및 성장기 어린이의 성장에 도움이 되는 신규한 비피더스균 균주를 제공하는 것이다.SUMMARY OF THE INVENTION It is an object of the present invention to provide a novel bifidobacteria strain which is useful for the growth of newborn babies, infants, children and growing children.
본 발명의 다른 목적은 모유 올리고당의 소화를 돕고, 비타민의 합성을 촉진하며, 질소원의 리사이클링에 기여하고, 유해 세균의 증식을 억제함으로써, 영유아, 어린이 및 청소년들의 성장을 촉진할 수 있는 기능성 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a functional food composition capable of promoting growth of infants, children and adolescents by helping the digestion of milk oligosaccharides, promoting the synthesis of vitamins, contributing to recycling of nitrogen sources, and inhibiting the growth of harmful bacteria .
상술한 목적을 달성하기 위한 본 발명의 하나의 양상은 한국생명공학연구원 유전자은행(Korean Collection for Type Culture; KCTC)에 수탁 번호 KCTC 11859BP로서 국제기탁된 비피도박테리움 롱굼 인판티스 CBT BT1(Bifidobacterium longum bv. infantis CBT BT1) 비피더스균에 관한 것이다. One aspect of the present invention for achieving the above object is to provide a method for screening a Bifidobacterium (Bifidobacterium) strain deposited with the Korean Collection for Type Culture (KCTC) under accession number KCTC 11859BP Longong Infante Tees CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) bifidobacteria.
본 발명의 다른 양상은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1(Bifidobacterium longum bv. infantis CBT BT1)의 균주를 포함하는 영유아, 어린이 및 청소년들의 성장을 촉진할 수 있는 기능성 식품 조성물을 제공하는 것이다. Another aspect of the present invention is the use of the Bifidobacterium Longong Infante Tees CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1). The present invention also provides a functional food composition capable of promoting growth of infants, children and adolescents.
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1(Bifidobacterium longum bv. infantis CBT BT1)의 균주는 산업적 규모로 대량 생산이 안 되고, 인간 효소에 의해서 소화되지 않는 모유 올리고당(Human Milk Oligosaccharide)을 소화시켜 공급하고, 비타민의 생합성을 촉진하며, 장내 유해세균의 증식을 억제하고, 면역계를 조절하여 성장 촉진 효능이 우수하다. The Bifidobacterium Longong Infante Tees CBT BT1 (Bifidobacterium longum bv. The strains of infantis CBT BT1) are not mass-produced on an industrial scale, digest and feed human milk oligosaccharides that are not digested by human enzymes, promote vitamin biosynthesis, inhibit the growth of intestinal harmful bacteria And has excellent growth-promoting effect by regulating the immune system.
본 발명의 성장촉진용 기능성 식품 조성물은 신생아 및 영유아, 어린이 및 청소년의 체내 대사를 균형적으로 활성화시키고 면역계를 조절하여 성장 발육에 도움을 줄뿐만 아니라 두뇌 발달도 촉진할 수 있다. 또한 본 발명의 성장촉진용 기능성 식품 조성물은 성장부진, 발육부진, 체력저하, 저체중을 개선할 수 있다. The functional food composition for growth promotion of the present invention is capable of promoting brain growth as well as assisting in growth and development by regulating the metabolism of the neonatal, infant, child and adolescents in the body and controlling the immune system. In addition, the functional food composition for growth promotion of the present invention can improve growth retardation, poor growth, physical strength, and low weight.
도 1a는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) KCTC 11859BP 균주의 16S rRNA 서열이다.
도 1b-c는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1과 관련 종들의 16S rRNA 서열의 상동성 및 계통발생적 관계(phylogenetic relationship)를 비교 도시한 것이다.
도 2는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈 DNA의 RAPD(Random Amplified Polymorphic DNA) 분석 결과이다.
도 3은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) KCTC 11859BP 균주의 지놈 DNA의 PFGE(Pulsed Field Gel Electrophoresis) 분석 결과이다.
도 4는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) KCTC 11859BP 균주의 용혈성 활성(hemolytic activity) 분석 결과이다.
도 5는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주 및 관련 비피도박테리움 롱굼 균주들의 계통발생 트리를 도시한 것이다.
도 6은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 모유 올리고당 대사와 관련된 유전자의 수를 나타낸 도면이다.
도 7은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 우레아 대사와 관련된 유전자의 수를 나타낸 모식도이다.
도 8은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 2차 대사산물 생합성 유전자를 도시한 도면이다.
도 9a-b는 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 마우스 생장에 미치는 성장 촉진 효과를 나타낸 그래프이다. ≪ RTI ID = 0.0 > 1A < / RTI > Longong Infante tooth BT1 CBT (Bifidobacterium longum bv. Infantis CBT BT1) is a 16S rRNA sequence of the strain KCTC 11859BP.
Figures 1b-c show the Bifidobacterium Longong The comparison of the homology and phylogenetic relationship of the 16S rRNA sequence of the relevant species with the citrate CBT BT1.
FIG. 2 is a graph showing the activity of the Bifidobacterium Longong Infante a RAPD (Random Amplified Polymorphic DNA) analysis of the genome DNA of the tooth BT1 CBT strain.
Figure 3 is a graphical representation of the Bifidobacterium Longong Infante tooth BT1 CBT (Bifidobacterium longum bv. Infantis CBT BT1) is PFGE (Pulsed Field Gel Electrophoresis) analysis of the genomic DNA of the strain KCTC 11859BP.
Figure 4 is a graphical representation of the Bifidobacterium Longong Infante Tees CBT BT1 (Bifidobacterium longum bv. Infantis CBT BT1) KCTC 11859BP strain.
Figure 5 is a graphical representation of the Bifidobacterium Longong Infectis CBT BT1 strain and related Bifidobacterium The phylogenetic tree of Longgum strains is shown.
FIG. 6 is a graph showing the activity of the Bifidobacterium Longong This figure shows the number of genes involved in breast milk oligosaccharide metabolism of the infantis CBT BT1 strain.
Figure 7 is a graphical representation of the Bifidobacterium Longong Is a schematic diagram showing the number of genes involved in the urea metabolism of the intactis CBT BT1 strain.
Figure 8 is a graphical representation of the Bifidobacterium Longong Lt; RTI ID = 0.0 > CBT < / RTI > BT1 strain.
Figures 9a-b show the effect of the Bifidobacterium Longong A graph showing the growth-promoting effect on the growth of mouse Infante tooth BT1 CBT strain.
이하에서 본 발명에 대해서 더욱 상세하게 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 하나의 양상은 성장촉진 효능이 우수한 한국생명공학연구원 유전자은행(Korean Collection for Type Culture; KCTC)에 수탁 번호 KCTC 11859BP로서 국제기탁된 비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) 비피더스균이다. One aspect of the present invention relates to a method for inhibiting the growth of a host cell, which has been deposited with the Korean Collection for Type Culture (KCTC), which has excellent growth-promoting effect, as Accession No. KCTC 11859BPBifidobacterium Longong Infantis CBT BT1 (Bifidobacterium longum bv.infantis CBT BT1) bifidobacteria.
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 인간 효소에 의해서는 분해되지 않고, 구조가 매우 다양하고 복잡하여 산업적으로 대량생산이 어려운 모유 올리고당(HMO)을 분해하여 그러한 균주를 섭취하는 유아나 소아에게 모유 올리고당을 공급함으로써 성장을 촉진시킬 수 있다. The Bifidobacterium longum infantis CBT BT1 strain of the present invention is a strain that does not decompose by human enzymes but decomposes mammalian oligosaccharide (HMO), which is very diverse and complex in structure and which is industrially difficult to mass-produce, It is possible to promote growth by feeding milk oligosaccharide to a child.
사람의 모유는 유익한 기능을 갖는 200 종류 이상의 다양한 올리고당을 포함하는 것으로 알려져 있다. 모유 올리고당(Human Milk Oligosaccharide)은 유익한 장내 미생물총의 증식 및 번식을 촉진하고, 유해 세균의 증식을 저해하며, 세포 반응의 조절자로 기능하고, 면역계를 조절하고, 신생아 및 유아의 두뇌 성장 발달의 필수성분으로 두뇌활동의 에너지를 공급함으로써 신생아 및 유아의 두뇌발달에 기여하는 것으로 알려져 있다. Human breast milk is known to contain more than 200 different oligosaccharides with beneficial functions. Human Milk Oligosaccharide promotes the proliferation and proliferation of beneficial intestinal microflora guns, inhibits the growth of harmful bacteria, functions as a regulator of cellular responses, regulates the immune system, and is essential for neonatal and infant brain growth development Is known to contribute to the brain development of neonates and infants by supplying the energy of brain activity as a component.
상기 모유 올리고당은 상부 위장관 및 소장에서의 효소 소화에 저항성이 있어서 결장까지 손상되지 않고 도달하여, 거기서 결장 발효에 대한 기질로서 기능한다. 사람의 모유는 병원성 미생물의 증식을 저지하는 바람직한 장내 세균총의 증식을 촉진하는 몇 개의 인자를 포함한다고 생각되고 있다. 모유 올리고당이 유익균의 수를 증가시키고 잠재적으로 병원성인 세균수를 감소시킬 수 있는 방법은 세포 표면 수용체에 대한 경쟁, 필수 영양소에 대한 경쟁, 항균제의 생성, 및 배설물의 pH를 낮추고 잠재적으로 병원성인 세균을 억제할 수 있는 단쇄 지방산 (SCFA)과 같은 억제성 화합물의 생성을 통해 일어난다. 모유 올리고당은 발효되어 아세트산, 프로피온산, 및 부티르산과 같은 SCFA를 생성한다. 이러한 SCFA는 열량에 기여하고, 장 상피에 대한 주요 에너지원으로서 기능하고, 결장 내 나트륨 및 물의 흡수를 촉진하며, 소장의 소화 및 흡수를 강화시키는 것으로 생각된다. 또한, SCFA는 위장의 발달 및 면역 기능을 조절함으로써 전반적인 위장 건강에 기여한다.The milk oligosaccharides are resistant to digestion of enzymes in the upper gastrointestinal tract and small intestine, reaching the colon without damage, and functioning as a substrate for colon fermentation there. It is believed that human milk contains several factors that promote the growth of the desired intestinal flora that prevents the growth of pathogenic microorganisms. Methods that can increase the number of beneficial bacteria and decrease the number of potentially hospital-acquired bacteria in breast milk oligos are the competition for cell surface receptors, the competition for essential nutrients, the production of antimicrobial agents, and the pH of excreta, Such as short chain fatty acids (SCFA), which can inhibit < RTI ID = 0.0 > a < / RTI > Milk oligosaccharides ferment and produce SCFA, such as acetic acid, propionic acid, and butyric acid. It is believed that such SCFA contributes to calories, acts as a major energy source for the intestinal epithelium, promotes absorption of sodium and water in the colon, and enhances digestion and absorption of the small intestine. In addition, SCFA contributes to overall gastrointestinal health by regulating gastrointestinal development and immune function.
모유 올리고당(HMO)은 다양한 구조의 올리고당으로 구성되는데, 주로 다섯 개의 단당류: D-글루코오스 (Glc), D-갈락토오스 (Gal), N-아세틸글루코사민(GlcNAc), L-푸코스(Fuc)와 살리실산(Sia; N-아세틸 뉴라미닉 애시드[Neu5Ac])으로 구성되어 있다. Milk oligosaccharides (HMO) are composed of oligosaccharides of various structures, mainly consisting of five monosaccharides: D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L- (Sia; N-acetylneuraminic acid [Neu5Ac]).
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈은, 모유 올리고당(HMO)의 소화 효소를 코드화하는 여러 가지 종류의 유전자를 포함한다. 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈은, α-만노시다아제, β-만노시다아제, 엔도-β-N-아세틸글루코사미니다아제, 엔도-α-N-아세틸갈락토사미니다아제, 시알리다아제, α-푸코시다아제, α-N-아세틸글루코사미니다아제, β-N-아세틸글루코사미니다아제, 및 β-N-아세틸헥소사미니다아제를 코드화하는 유전자를 포함한다. The Bifidobacterium Longong Infante genome tooth BT1 CBT strain, a gene that codes the different types of digestive enzymes in the human milk oligosaccharides (HMO). The genome of the Bifidobacterium longum infantis CBT BT1 strain of the present invention is selected from the group consisting of α -mannosidase, β -mannosidase, endo- β - N -acetylglucosaminidase, endo- α - N -acetylgalacto Sami the kinase, sialidase, α - Foucault let kinase, α - N - acetyl glucosyl Sami the kinase, β - N - acetyl glucosyl Sami the kinase, and β - N - acetyl cyclohexyl containing a gene encoding a sosami is kinase do.
또한 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈은, 비타민, 특히 비타민 B 군을 합성하는 유전자를 갖는다. 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈에는 세 종류의 비타민을 합성할 수 있는 유전자가 존재한다. 구아노신 5'-트리포스페이트 (GTP)로부터 폴레이트를 합성하고, 코리스메이트로부터 폴레이트(B9)를 합성하고, L-아스파테이트로부터 니코틴산(B3)을 합성하며, D-리불로스 5-포스페이트 및 GTP로부터 리보플라빈(B2)을 합성할 수 있다. Also, the Bifidobacterium Longong Infante genome tooth BT1 CBT strain has vitamins, in particular the gene for synthesizing vitamin B group. In the genome of the Bifidobacterium longum infantis CBT BT1 strain of the present invention, there exists a gene capable of synthesizing three kinds of vitamins. Synthesis of folate from guanosine 5'-triphosphate (GTP), synthesis of folate (B9) from cholestate, synthesis of nicotinic acid (B3) from L-aspartate, synthesis of D-ribulose 5-phosphate and Riboflavin (B2) can be synthesized from GTP.
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주에 의한 모유 올리고당의 발효는 또한 배설물 중 주요 악취 성분으로서 연관되어 왔던 배설물의 암모니아, 아민 및 페놀의 농도를 감소시킬 수 있다. 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 우레아제 단백질을 코드화하는 ure 유전자 및 우레아 이송 단백질을 코드화하는 urt 유전자를 갖는다. 이러한 유전자는 다른 비피도박테리움속 균주에는 발견되지 않는 것으로, 본 발명의 균주가 다른 균주들에 비해 영양분을 더 효율적으로 이용가능하고, 질소원의 리사이클링에 관여한다는 것을 시사한다. The Bifidobacterium Longong Infante tooth fermentation of breast milk oligosaccharides by CBT BT1 strain is also possible to reduce the ammonia concentration of the amine and the phenol of the slurry, which has been associated with a major odorous components of feces. The Bifidobacterium longum infantis CBT BT1 strain of the present invention has a ure gene encoding a urease protein and a urt gene encoding a urea transfer protein. These genes are not found in other strains of Bifidobacterium sp., Suggesting that the strains of the present invention are more efficiently available for nutrients than other strains and are involved in the recycling of nitrogen sources.
도 8에 도시된 바와 같이, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 박테리오신, 렌티펩타이드, 및 비-리보좀 펩타이드(non-ribosomal peptides) 및 폴리케타이드의 생합성을 위한 단백질을 코드화하는 유전자를 갖는다. 본 발명의 균주는 박테리오신-코드화 유전자, 페나진(phenazine) 생합성을 위한 단백질을 코드화하는 유전자, 폴리케타이드 및 비-리보좀 펩타이드를 코드화하는 유전자를 갖는다. As shown in Figure 8, the Bifidobacterium Longong The Phytate CBT BT1 strain has a gene encoding a protein for biosynthesis of bacteriocins, lentipeptides, and non-ribosomal peptides and polyketides. The strain of the present invention has a bacteriocin-encoding gene, a gene encoding a protein for phenazine biosynthesis, a gene encoding a polyketide and a non-ribosomal peptide.
본 발명의 다른 양상에 따르면, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 프로바이오틱 비피더스균으로 사용되거나, 다양한 유제품 및 기타 발효 제품에 사용할 수도 있다. According to another aspect of the present invention, the Bifidobacterium longum infantis CBT BT1 strain of the present invention can be used as probiotic bifidobacteria, or in various dairy products and other fermented products.
본 발명의 다른 양상은 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주를 포함하는 성장촉진용 기능성 식품 조성물에 관한 것이다. 모유 올리고당(HMO)은 현재로서는 대량 생산이나 상업적 이용이 불가능하여 대부분의 조제유 또는 조제식에는 결핍되어 있다. 모유 올리고당(HMO)은 영유아의 필수 영양원이지만 인간 효소에 의해서는 소화가 되지 않고, 소화되지 않을 경우 분변으로 배설된다. 본 발명의 성장촉진용 기능성 식품 조성물은 모유 올리고당을 소화시켜서 공급함으로써 신생아 및 영유아의 두뇌발달 및 성장발육을 촉진할 수 있다. 상기 식품 조성물은 식품, 건강기능식품(nutraceutical), 보충제(supplement), 생균제 또는 공생제(symbiotic)이다. 본 명세서에서 "생균제"라는 용어는 적합한 양으로 공급되는 경우, 숙주 생물의 건강에 유익한 살아있는 미생물을 의미한다. 본 명세서에서, "공생제"라는 용어는 프리바이오틱(prebiotic) 및 생균제의 혼합물을 함유하는 식품들을 의미한다. Another aspect of the present invention relates to a functional food composition for growth promotion comprising the Bifidobacterium longum infantis CBT BT1 strain of the present invention. Milk oligosaccharides (HMOs) are currently not available for mass production or commercial use and are deficient in most formula or formula. Milk oligosaccharides (HMOs) are essential nutrients for infants and children, but are not digested by human enzymes and are excreted as feces if not digested. The functional food composition for growth promotion of the present invention can promote the brain development and growth of newborn babies and infants by feeding the milk oligosaccharide by digesting it. The food composition is a food, a nutraceutical, a supplement, a probiotic or a symbiotic. The term "probiotic agent" as used herein refers to a live microorganism that is beneficial to the health of the host organism when supplied in an appropriate amount. As used herein, the term "symbiotic" refers to foods containing a mixture of prebiotic and probiotic.
본 발명의 조성물은 실시예에 따라서 비피도박테리움 롱굼 인판티스 CBT BT1 균주 이외에 락토바실루스 살리바리우스(Lactobacillus salivarius), 락토바실루스 브레비스(Lactobacillus brevis), 락토바실루스 헬베티쿠스(Lactobacillus helveticus), 락토바실루스 퍼멘툼(Lactobacillus fermentum), 락토바실루스 파라카세이(Lactobacillus paracasei), 락토바실루스 카세이(Lactobacillus casei), 락토바실루스 델브루에키(Lactobacillus delbrueckii), 락토바실루스 레우테리(Lactobacillus reuteri), 락토바실루스 부츠네리(Lactobacillus buchneri), 락토바실루스 가세리(Lactobacillus gasseri), 락토바실루스 존스니(Lactobacillus johonsonii), 락토바실루스 케피르(Lactobacillus kefir), 락토코쿠스 락티스(Lactococcus lactis), 비피도박테리움 비피둠(Bifidobacterium bifidum), 비피 도박테리움 수도롱굼(Bifidobacterium pseudolongum), 비피도박테리움 써모필룸 (Bifidobacterium themophilum), 비피도박테리움 아돌센티스 (Bifidobacterium adolescentis)로 구성되는 군에서 선택되는 1종 이상의 프로바이오틱 유산균을 추가로 포함할 수 있다. The compositions of the present invention bipyridinium gambling according to the embodiment te Solarium ronggum Infante tooth CBT BT1 strains other than Lactobacillus raised Bari right switch (Lactobacillus salivarius), Lactobacillus brevis (Lactobacillus brevis), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus Bacillus spread lactofermentum (Lactobacillus fermentum), Lactobacillus para casein is (Lactobacillus paracasei), Lactobacillus Kasei (Lactobacillus casei), Lactobacillus del Brew Station (Lactobacillus delbrueckii), Lactobacillus Leu Terry (Lactobacillus reuteri), Lactobacillus boots Tenerife ( Lactobacillus buchneri), Lactobacillus joined Lee (Lactobacillus gasseri), Lactobacillus Jones you (Lactobacillus johonsonii), Lactobacillus Kane pireu (Lactobacillus kefir), Nose Lactobacillus Syracuse Lactis (Lactococcus lactis), Bifidobacterium BP Doom (Bifidobacterium bifidum), Bifidobacterium may ronggum (Bifidobacterium pseudolongum), Bifidobacterium write a brush room (B ifidobacterium themophilu m), Bifidobacterium Adolfo sentiseu (one or more kinds selected from a group consisting of Bifidobacterium adolescentis) Pro Bio A lactic acid bacteria may be further included.
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 비피더스균의 배양에 통상 이용되는 배지를 사용하여 통상 사용되는 조건 하에서 배양함으로써 증식하여 회수할 수 있다. 배양 후 얻어지는 배양물을 그대로 사용해도 되고 나아가 필요에 따라 원심분리 등에 의한 조(粗)정제 및/또는 여과 등에 의한 고액분리나 멸균조작을 행해도 된다. 바람직하게는 원심분리를 행하여 비피더스균의 균체만을 회수한다. 아울러 본 발명에서 사용하는 비피더스균은 습윤 균체여도 되고 또는 건조 균체여도 된다. 예컨대, 동결건조에 의해 생균제 형태로 제조하여 이용될 수 있다.The Bifidobacterium longum infantis CBT BT1 strain of the present invention can be recovered by growing it by culturing under the usual conditions using a culture medium commonly used for culturing bifidobacteria. The culture obtained after cultivation may be used as is, or further subjected to solid-liquid separation or sterilization by, for example, rough purification by centrifugation or the like and / or filtration. Preferably, centrifugation is carried out to recover only the bacterium cells. In addition, the bifid bacteria used in the present invention may be wet cells or dried cells. For example, it can be prepared into a biocide form by lyophilization and used.
본 발명의 조성물은 비피도박테리움 롱굼 인판티스 CBT BT1 균주 이외에 통상적인 담체 또는 부형제를 추가로 포함할 수 있으며, 이 외에도 바인더, 분해제, 코팅제, 윤활제 등과 같은 통상적으로 사용되는 다양한 첨가제와 제형화되어 조제될 수 있다. The compositions of the present invention may be used to treat < RTI ID = Longong In addition to the conventional flour and the excipient CBT BT1, they may be formulated with various additives commonly used such as binders, disintegrating agents, coating agents, lubricants and the like in addition to conventional carriers or excipients.
본 발명의 조성물은 상기 비피도박테리움 롱굼 인판티스 CBT BT1 균주와 적절한 담체, 부형제, 보조 유효 성분 등과의 혼합에 의하여 분말제, 과립제, 정제, 캡슐 또는 액상의 형태로 제형화될 수 있다. 또한 본 발명의 균주는 공지의 방법을 사용하여, 위장을 통과한 뒤 대장에 도달하여 활성 성분인 비피더스균이 신속하게 장내에 방출되도록 장용 피복되어 제품화될 수 있다. The composition of the present invention can be used to treat < RTI ID = Longong Infante tooth BT1 CBT may be strains with a suitable carrier, excipient and powder, by mixing as a secondary active ingredient, granules, tablets, formulations in the form of a capsule or liquefaction. In addition, the strain of the present invention can be commercialized using a known method after being passed through the stomach and reaching the large intestine so that the bifid bacteria as an active ingredient is quickly released into the intestines.
본 발명에서 사용가능한 부형제는 수크로오스, 락토오스, 만니톨, 글루코오스 등과 같은 설탕 및 옥수수 전분, 감자 전분, 쌀 전분, 부분적으로 전젤라틴화된 전분 등의 전분을 포함한다. 바인더는 덱스트린, 소듐알지네이트, 카라지난, 구아검, 아카시아, 아가 등의 다당류, 트라가칸트, 젤라틴, 글루텐 등의 천연-발생 거대분자 물질, 히드록시프로필셀룰로오스, 메틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 에틸셀룰로오스, 히드록시프로필 에틸셀룰로오스, 카복시메틸셀룰로오스소듐 등의 셀룰로오스 유도체 및 폴리비닐피롤리돈, 폴리비닐알코올, 폴리비닐아세테이트, 폴리에틸렌글리콜, 폴리아크릴산, 폴리메타크릴산 및 비닐아세테이트 수지 등의 고분자를 포함한다.Excipients usable in the present invention include sugars such as sucrose, lactose, mannitol, glucose and the like and starches such as corn starch, potato starch, rice starch, and partially pregelatinized starch. The binder may be selected from natural-occurring macromolecular substances such as dextrin, sodium alginate, carrageenan, guar gum, acacia and agar, polysaccharides such as tragacanth, gelatin and gluten, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, Cellulose derivatives such as ethyl cellulose, hydroxypropyl ethyl cellulose and carboxymethyl cellulose sodium, and polymers such as polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyethylene glycol, polyacrylic acid, polymethacrylic acid and vinyl acetate resin .
분해제로는 카복시메틸셀룰로오스, 카복시메틸셀룰로오스칼슘, 저치환 히드록시프로필셀룰로오스 등의 셀룰로오스 유도체 및 소듐카복시메틸 전분, 히드록시프로필 전분, 옥수수 전분, 감자 전분, 쌀 전분 및 부분적으로 전젤라틴화된 전분 등의 전분을 사용할 수 있다.Examples of the decomposing agent include cellulose derivatives such as carboxymethylcellulose, carboxymethylcellulose calcium and low substituted hydroxypropylcellulose, and sodium carboxymethyl starch, hydroxypropyl starch, corn starch, potato starch, rice starch and partially pregelatinized starch Of starch can be used.
본 발명에서 사용가능한 윤활제의 예들은 활석, 스테아르산, 칼슘스테아레이트, 마그네슘스테아레이트, 콜로이드성 실리카, 히드로스실리콘다이옥사이드, 다양한 종류의 왁스 및 히드로게네이티드 오일 등을 포함한다.Examples of lubricants that can be used in the present invention include talc, stearic acid, calcium stearate, magnesium stearate, colloidal silica, hydrous silicon dioxide, various types of waxes and hydrogenated oils and the like.
코팅제로는 디메틸아미노에틸메타크릴레이트-메타크릴산 공중합체, 폴리비닐아세탈디에틸아미노아세테이트, 에틸아크릴레이트-메타크릴산 공중합체, 에틸아크릴레이트-메틸메타크릴레이트-클로로트리메틸암모늄에틸메타크릴레이트 공중합체, 에틸셀룰로오스 등의 수불용성 중합체, 메타크릴산-에틸아크릴레이트 공중합체, 히드록시프로필메틸셀룰로오스프탈레이트, 히드록시프로필메틸셀룰로오스아세테이트석시네이트 등의 장성 중합체 및 메틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 폴리비닐피롤리돈, 폴리에틸렌글리콜 등의 수용성 중합체를 포함하나, 반드시 이들로 제한되는 것은 아니다. Examples of the coating agent include dimethylaminoethyl methacrylate-methacrylic acid copolymer, polyvinyl acetal diethylaminoacetate, ethyl acrylate-methacrylic acid copolymer, ethyl acrylate-methyl methacrylate-chlorotrimethylammonium ethyl methacrylate A water-insoluble polymer such as a copolymer, a water-insoluble polymer such as ethylcellulose, a methacrylic acid-ethyl acrylate copolymer, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate and the like and a thickener such as methylcellulose, hydroxypropylmethylcellulose , Polyvinyl pyrrolidone, polyethylene glycol, and the like, but are not limited thereto.
본 발명의 성장촉진용 조성물에서 유효성분인 상기 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 함량은 체중, 연령이나 성별 등을 고려하여 적절하게 결정될 수 있다. 일례로, 본 발명의 조성물은 조성물 총 중량에 대해, 유효성분으로서 비피도박테리움 롱굼 인판티스 CBT BT1 균주를 영양적으로 유효한 농도로 포함하는데, 바람직하게는 108 내지 1012 cfu/g의 함량으로 포함하거나, 동등한 수의 생균을 가진 배양물을 포함한다. 일반적으로, 성인의 경우, 1×106 이상의 생균, 바람직하게는 1×108 내지 1×1012의 생균이 필요에 따라 한번 또는 수차례에 걸쳐서 나누어서 투여될 수 있다.In the composition for growth promotion of the present invention, the content of the Bifidobacterium longum infantis CBT BT1 strain as an active ingredient can be appropriately determined in consideration of body weight, age, sex, and the like. As an example, the composition of the present invention may contain, as an active ingredient, Bifidobacterium longum It contains nutritionally effective concentrations of the citrate CBT BT1 strain, preferably at a content of 10 8 to 10 12 cfu / g, or includes cultures with an equivalent number of viable bacteria. Generally, in the case of an adult, viable cells of 1 x 10 6 or more, preferably 1 x 10 8 to 1 x 10 12 viable cells may be administered once or several times, as needed.
또 다른 양상에서, 본 발명의 성장촉진용 기능성 식품 조성물은 비피도박테리움 브레베 CBT BR3(Bifidobacterium breve CBT BR3)(KCTC 12201BP), 비피도박테 리움 비피둠 CBT BF3(KCTC 12199BP)), 및 비피도박테리움 롱굼 CBT BG7(KCTC 12200BP)으로 구성되는 군에서 선택되는 하나 이상의 다른 프리바이오틱 (prebiotic)을 추가로 포함할 수 있다. 이러한 조성물은 각각의 비피더스균을 동일한 비율로 포함할 수 있다. In yet another aspect, a composition for promoting growth functional food of the present invention is non-blooming gambling Te Solarium breve CBT BR3 (Bifidobacterium breve CBT BR3) (KCTC 12201BP), Bifidobacterium Bifidobacterium Doom CBT BF3 (KCTC 12199BP), and Bifidobacterium And Longchum CBT BG7 (KCTC 12200BP). ≪ RTI ID = 0.0 > [0031] < / RTI > Such a composition may comprise the same proportion of each bifidus.
이하에서 본 발명을 실시예에 의해 상세히 설명한다. 다만, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해서 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the contents of the present invention are not limited by the following examples.
실시예Example
실시예Example 1. One. 비피도박테리움Bifidobacterium 롱굼Longong 인판티스Infantis CBT BT1( CBT BT1 ( BifidobacteriumBifidobacterium longumlongum bv. infantis CBT BT1) 균주의 분리 및 동정bv. Isolation and identification of infantis CBT BT1) strain
1-1. 균주의 선발1-1. Selection of strain
건강한 아기의 분변 1g을 멸균 혐기수에 연속 희석(serial dilution)한 후 각 희석액 1㎖을 Man-Rogosa-Sharpe(MRS. BD. USA) 고체 배지에 부어서 혐기 조건에서 3일간 배양하였다. 생성된 콜로니를 MRS에 BCP(Bromocresol purple, 0.17g/L)가 첨가된 비피더스균 선택배지(BL 고체배지)에 옮긴 후 같은 조건에서 3일간 배양하였다. BCP 지시약은 유산균이 젖산을 형성하여 주변 pH가 낮아지면 보라색에서 노란색으로 변하게 된다. 콜로니 주변의 색이 노란 색으로 변한 유산균 콜로니를 선택한 후 생화학적, 분자생물학적 동정을 진행하였고, 이 후 균주의 기능성 및 안정성이 가장 우수한 균주 1종을 최종 선발하였다.One gram of healthy baby's feces was serially diluted in sterile anaerobic water and 1 ml of each dilution was poured into a solid medium of Man-Rogosa-Sharpe (MRS, BD, USA) and incubated for 3 days in anaerobic condition. The resulting colonies were transferred to a bifidobacterial selection medium (BL solid medium) to which BCP (Bromocresol purple, 0.17 g / L) was added to MRS and then cultured for 3 days under the same conditions. The BCP indicator changes from purple to yellow when the lactic acid bacteria form lactic acid and the surrounding pH is lowered. The colony was transformed into a yellow color, and biochemical and molecular biochemical identification was carried out. One strain with the best functionality and stability was finally selected.
1-2. 선발된 균주의 동정1-2. Identification of selected strains
1) API 키트를 이용한 생화학적 동정1) Biochemical identification using API kit
선발된 균주의 당 이용성을 알아보기 위하여 API 50 CHL Carbohydrate Test Kit(bioMerieux Co., France)를 이용하였다. 10 ㎖의 MRS(Man-Rogosa-Sharpe) 액체배지에서 37℃에서 17시간 배양한 후, 1 ㎖의 배양액을 회수하여 CHL 용액으로 2회 세정하였다. 이어서 원심분리(MICRO-17, Hanil, KR)에 의해 균체를 모아 9 ㎖의 CHL 용액에 재현탁시켰다. 150 ㎕의 균주 현탁액을 API 50 CHL 키트의 각 웰에 넣은 후, 오토클레이브한 파라핀 오일을 웰 내의 균주 현탁액 위에 분주하였다. 37℃에서 3일간 배양한 후 각각의 당 이용성을 비교하였다. 49가지 탄소원에 대하여 미생물 증식에 의한 색의 변화 여부를 관찰하여 각 탄소원의 이용 여부를 관찰하였고, 최종 동정 결과는 동정용 프로그램 API web을 이용하여 해석하여 그 결과를 하기 표 1 및 표 2에 나타내었다. 동정 결과, 선발된 균주는 B. infan tisT (ATCC 15697)와 99.9% 동일한 생화학적 특성을 보였다. The API 50 CHL Carbohydrate Test Kit (bioMerieux Co., France) was used to determine the sugar availability of selected strains. After culturing in 10 ml of MRS (Man-Rogosa-Sharpe) liquid medium at 37 ° C for 17 hours, 1 ml of the culture broth was collected and washed twice with CHL solution. The cells were then collected by centrifugation (MICRO-17, Hanil, KR) and resuspended in 9 mL of CHL solution. 150 [mu] L of strain suspension was placed in each well of the API 50 CHL kit, and autoclaved paraffin oil was dispensed onto the strain suspension in the wells. After 3 days of incubation at 37 ° C, the sugar availability was compared. 49 carbon sources were observed for the change of color due to microbial growth, and the use of each carbon source was observed. The results of the final identification were analyzed using the identification program API web, and the results are shown in Tables 1 and 2 . As a result of the identification, the selected strain showed the same biochemical characteristics as B. infan tisT (ATCC 15697) at 99.9%.
본 발명의 균주의 당 이용성을 B. infantis T (ATCC 27920) 및 B. longum T (ATCC 15707)의 당 이용성과 비교하였다. Bergy's Manual 및 기타 문헌을 참고하면, 아라비노오스, 및 멜레지토오스를 발효시키지 못하는 비피더스균은 비. 인판티스로 분류되어야 하고, 양자를 모두 발효시키는 비피더스균은 비. 롱굼 균주로 분류되어야 한다. 본 발명의 균주는 하기 표 2와 같이 아라비노오스, 및 멜레지토오스를 탄소원 및 에너지원으로 이용하지 못하기 때문에, 비. 인판티스에 속하는 것이 확실하다. The availability of each of the present invention was compared using the strain B. and each of T infantis (ATCC 27920), and B. longum T (ATCC 15707). Bergy ' s Manual and other references, bifidobacteria that are unable to ferment arabinose and melezetose are non- fermentable . It is classified as Infante Tees and bifidobacteria that all the bilateral non-fermentation. Longgum strains should be classified as. An arabinose, and Mel register Sat agarose, such as the strain of the present invention in Table 2 because it does not use as a carbon and energy source, non. It is certain that it belongs to infantis .
CBT BT B. longum infantis
CBT IT
2) 16s 2) 16s rDNArDNA 유전자 염기서열 결정을 통한 동정 Identification through gene sequencing
분리된 균주로부터 지놈 DNA를 추출하여 16s rRNA 염기서열을 분석하였다. 분변에서 분리한 균주의 순수 배양액 1㎖에서 Accuprep 지놈 추출 키트(Bioneer, Korea)를 이용하여 지놈 DNA를 추출하였다. 추출한 DNA를 주형으로 16s rRNA 영역을 프라이머 F (5'-AAGGAGGTGATCCAGCC-3')3와 프라이머 R(5'-AAGGAGGTGATCCAGCC-3')3을 이용하여 PCR (MyCycler, BIO-RAD, USA)을 수행하였다. Genomic DNA was extracted from isolated strains and analyzed for 16s rRNA sequences. Genomic DNA was extracted from 1 ml of the pure culture of the strain isolated from the feces using Accuprep genome extraction kit (Bioneer, Korea). (MyCycler, BIO-RAD, USA) was performed using primers F (5'-AAGGAGGTGATCCAGCC-3 ') 3 and primer R (5'-AAGGAGGTGATCCAGCC-3') 3 in the 16s rRNA region using the extracted DNA as a template .
PCR 산물은 pGEM-Teasy 벡터(Promega, USA)에 연결하여 E.coli 균주 DH5α에 형질전환시킨 후 LB/x-gal/ampplate에 도말하여 37℃에서 밤새 배양하였다. 스크리닝을 통하여 형질전환체로부터 삽입체를 포함하는 재조합 플라스미드를 분리한 후, DNA 염기서열 분석을 진행하였다. DNA 염기서열 분석은 DNA star program의 Cluster V method를 이용하여 비피도박테리움 인판티스 T (ATCC 15697)와 상동성을 비교하였다. 분리된 균주의 16s rRNA 염기서열은, 도 1b에 도시된 바와 같이, 비피도박테리움 인판티스 T(ATCC 15697)와 99.5%의 상동성을 보였다.The PCR product was ligated to pGEM-Teasy vector (Promega, USA), transformed into E. coli strain DH5α, plated on LB / x-gal / ampplate and incubated overnight at 37 ° C. After the recombinant plasmid containing the insert was isolated from the transformant through screening, DNA sequencing was performed. DNA sequence analysis was performed using the Cluster V method of the DNA star program to compare homology with Bifidobacterium infantis T (ATCC 15697). The 16s rRNA sequence of the isolated strain showed 99.5% homology with Bifidobacterium infantis T (ATCC 15697) as shown in Fig. 1B.
상기 분리된 균주와 관련 종들을 이용하여 계통발생 트리를 제작해 본 결과, 도 1c에 도시된 바와 같이, 분리된 균주와 비피도박테리움 인판티스 T는 하나로 묶일 수 있어, 분리된 균주는 비피도박테리움 인판티스 T와 보다 밀접하게 관련되는 것을 알 수 있다. As shown in FIG. 1C, the isolated strain and Bifidobacterium infantis T can be bound together. As a result, the isolated strain can be divided into Bifidobacterium It is more closely related to terbinafontis T.
3)3) RAPD (Random Amplified Polymorphic DNA)에 의한 DNA 지문 분석DNA fingerprint analysis by Random Amplified Polymorphic DNA (RAPD)
RAPD 분석은 분변에서 분리한 균주로부터 지놈 DNA를 추출하였으며, 분리한 DNA를 주형으로 (GTG)5 (5'-GTGGTGGTGGTGGTG-3') 프라이머를 이용하여 PCR-RAPD (MyCycler, BIO-RAD, USA)를 수행하였다. 최종 산물인 PCR 산물은 EtBr (ethidium bromide)에 염색 후 G:BOX (SYNGENE, UK)로 관찰하였다. RAPD 결과에서 분리한 균주는, 도 2에 도시된 바와 같이, 비피도박테리움 인판티스 T (ATCC 15697)와 다른 밴드 패턴을 보이고 있음을 확인할 수 있었다. 따라서 위 결과로부터 분변에서 분리한 균주는 비피도박테리움 인판티스 T (ATCC 15697)와 다른 신규 균주임을 확인하였다. 도 2에서 레인 1은 비피도박테리움 인판티스 T(ATCC 15697)의 결과이고, 레인 2는 비피도박테리움 롱굼 인판티스 CBT BT1(KCTC 11859BP)의 결과를 나타낸다.RAPD analysis was performed by PCR-RAPD (MyCycler, BIO-RAD, USA) using primers (GTG) 5 (5'-GTGGTGGTGGTGGTTG-3 ' Respectively. The final product, PCR product, was stained with EtBr (ethidium bromide) followed by G: BOX (SYNGENE, UK). As shown in FIG. 2, the strain isolated from the RAPD results showed a different band pattern from Bifidobacterium infantis T (ATCC 15697). Therefore, it was confirmed that the strain isolated from feces from the above results is a novel strain different from Bifidobacterium infantis T (ATCC 15697). In FIG. 2,
4) PFGE(Pulsed Field Gel Electrophoresis)에 의한 DNA 지문 분석 4) DNA fingerprint analysis by Pulsed Field Gel Electrophoresis (PFGE)
MRS broth에서 순수 배양된 비피도박테리움 롱굼 인판티스 CBT BT1, 및 비피도박테리움 인판티스 T (ATCC 15697)의 O.D.를 측정한 후 2% Low Melting Agarose를 이용하여 최종 O.D600=4에 맞춰 플러그(plug)를 제작하였다. 제작된 플러그를 1㎖ 라이소자임 완충액(2mg/㎖ Lysozyme (Sigma), 0.05% N-lauorylsarcosine (Sigma))에 넣고 4mg/㎖ Lysostaphin(sigma) 10 ㎕을 가한 후 37℃에서 밤새 반응시켰다. 플러그를 조심스럽게 꺼내 NDS 완충액(1 ㎖ 1M Tris-HCl(pH=8.0), 10 ㎖ 100% SDS, 89 ㎖ 0.5M EDTA(pH=8.5) 4 ㎖에 넣고 50℃에서 밤새 반응시켰다. 이후 가볍게 진탕하면서 50mM EDTA(pH 8.5) 10 ㎖에서 플러그를 6번 세정한 후 처리하고자 하는 효소 완충액 400 ㎕에 플러그를 조심스럽게 옮기고 상온에서 30분 방치한다. 플러그를 새로운 효소 완충액 400㎕에 옮긴 후 제한효소(20U)를 넣고 37℃에서 밤새 반응시켰다. 이 때 제한효소는 NotI을 사용하였다. 전기영동은 CHEF 시스템(BIO-RAD, USA)을 이용하여 0.5X TBE에서 5.3cm/V, 1s~15s 펄스 타임, 20 시간 동안으로 실시하였다. The pure cultured in MRS broth Bifidobacterium ronggum Infante tooth CBT BT1, and Bifidobacterium Infante teeth T then measuring the OD of (ATCC 15697) 2% Low Melting plug using Agarose according to the final OD 600 = 4 a plug was produced. The prepared plugs were placed in 1 ml lysozyme buffer (2 mg / ml Lysozyme (Sigma), 0.05% N-lauorylsarcosine (Sigma)) and 10 μl of 4 mg / ml Lysostaphin (Sigma) was added thereto and reacted overnight at 37 ° C. The plug was carefully removed and placed in 4 ml of NDS buffer (1 ml 1M Tris-HCl (pH = 8.0), 10 ml 100% SDS, 89 ml 0.5 M EDTA (pH = 8.5) and reacted overnight at 50 ° C. After washing the
전기영동이 완료된 후, EtBr 용액으로 염색한 후 G:BOX (SYNGENE, UK)로 밴드 패턴을 관찰하였다. NotI을 이용한 PFGE 결과, 분변에서 분리한 비피도박테리움 롱굼 인판티스 CBT BT1은 비피도박테리움 인판티스 T (ATCC 15697)와 상이한 밴드패턴을 보이는 새로운 균주임을 확인하였다. 도 3에서 레인 1은 비피도박테리움 인판티스 T(ATCC 15697)의 결과이고, 레인 2는 비피도박테리움 롱굼 인판티스 CBT BT1(KCTC 11859BP)의 결과를 나타낸다.After the electrophoresis was completed, the band pattern was observed with G: BOX (SYNGENE, UK) after staining with EtBr solution. As a result of PFGE using NotI, Fecal Bifidobacterium ronggum Infante Tees CBT BT1 is Bifidobacterium It was confirmed that this strain is a new strain showing a band pattern different from that of the infantis T (ATCC 15697). In Figure 3,
5) 기타 균학적 특성 5) Other mycological characteristics
본 발명에 따른 비피도박테리움 롱굼 인판티스 CBT BT1의 특성은 다음과 같다. Bifidobacterium according to the present invention Longong Infante Tees characteristics of CBT BT1 is as follows:
①세포의 형태: 간균
②운동성: 없음
③포자형성능: 없음
④그람(Gram) 염색: 양성When cultured in an anaerobic condition at 37 ° C for 2 days in a biel (BL) agar plate medium,
① Cell shape: Bacillus
② Mobility: None
③ Spore forming ability: None
④ Gram staining: positive
①형상: 원형
②융기: 볼록
③표면: 매끄러움(Smooth)When cultured in an anaerobic condition for 2 days at 37 ° C in a Biel (BL) agar plate medium,
① Shape: Circular
② Bump: convex
③ Surface: Smooth
최적 생장온도 37℃
② 생육 pH: 생장가능 생육 pH 5.0~7.5
최적 pH 6.0~6.5
③ 산소에 대한 영향: 혐기성① Growth temperature: Growth
Optimum growth temperature 37 ℃
② Growth pH: Growable growth pH 5.0 ~ 7.5
Optimum pH 6.0 to 6.5
③ Effect on oxygen: anaerobic
이상의 결과를 토대로 상기 분리된 균주를 "비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1)"균주로 명명하고, 2011년 3월 2일자로 대한민국 특허균주 기탁기관인 미생물자원센터(KCTC)에 기탁하여 수탁번호 KCTC 11859BP를 부여받았다. Based on the above results, the isolated strain was called " Bifidobacterium Longong Infante Tees CBT BT1 (Bifidobacterium longum bv . infantis CBT BT1) " and deposited on March 2, 2011 to the Microorganism Resource Center (KCTC), the depository of the Korean patented strain, and received the accession number KCTC 11859BP.
1-3. 기능성 및 안정성1-3. Functionality and stability
1) 항생제 내성 실험1) Antibiotic resistance test
분리된 비피도박테리움 롱굼 인판티스 CBT BT1(KCTC 11859BP)의 안전성을 검증하기 위해 항생제 내성을 분석하였다. 항생제 내성실험은 European Food Safety Authority (EFSA)에서 추천하는 micro-dilution 방법을 이용하여 수행하였으며, 실험에 사용된 항생제는 10종으로 암피실린(AMP), 반코마이신(VAN), 젠타미신(GEN), 카나마이신(KAN), 스트렙토마이신(STM), 에리트로마이신(ERM), 시너시드(Q/D), 클린다마이신(CLM), 테트라사이클린(TET) 및 클로람페니콜(CP)이다.Antibiotic resistance was analyzed to verify the safety of the isolated Bifidobacterium longum infantis CBT BT1 (KCTC 11859BP). Antibiotic resistance tests were carried out using the micro-dilution method recommended by the European Food Safety Authority (EFSA). Ten antibiotics were used: ampicillin (AMP), vancomycin (VAN), gentamicin (GEN), kanamycin (KAN), streptomycin (STM), erythromycin (ERM), cinnamic acid (Q / D), clindamycin (CLM), tetracycline (TET) and chloramphenicol (CP).
클린다마이신을 제외한 항생제에 대해서는 ISO-sensitest broth 10%와 MRS broth 90%를 혼합한 broth에 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 ㎍/㎖의 농도로 첨가하고, 클린다마이신은 락토바실루스 그룹의 EFSA 브레이크 포인트 값이 0.25 ㎍/㎖ 이하이기 때문에 항생제의 농도는 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125 ㎍/㎖의 농도로 첨가해 사용하였다. 또한, 시너시드는 BioMeriux 사의 E-테스트 스트립을 이용하여 진행하였다. For antibiotics except for clindamycin, the concentrations of 256, 128, 64, 32, 16, 8, 4, 2, 1 and 0.5 ㎍ / ㎖ were added to broth mixed with ISO-sensitized broth 10% and MRS broth 90% Since clindamycin has an EFSA breakpoint value of less than 0.25 μg / ml in the Lactobacillus group, antibiotics are added at concentrations of 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 and 0.03125 μg / Respectively. In addition, the thinner was carried out using an E-test strip of BioMeriux.
마이크로플레이트를 37℃하 혐기성 조건하에서 48시간 동안 인큐베이션하고, 이어서 MIC를 가시적인 성장이 관찰되지 않는 최저 항생제 농도로 측정하였다. EFSA 브레이크포인트에 기초하여, 비피도박테리움 롱굼 인판티스 CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1)가 각각의 항생제에 대해서 내성이 있는지 여부를 확인하여 하기 표 4에 나타내었다. The microplate was incubated at 37 캜 under anaerobic conditions for 48 hours, and then the MIC was measured at the lowest antibiotic concentration at which no visible growth was observed. Based on the EFSA breakpoints, Bifidobacterium ronggum Infante Tees CBT BT1 (Bifidobacterium longum bv. infantis CBT BT1) was confirmed to be resistant to each antibiotic, and is shown in Table 4 below.
CBT BT1 B. longum infantis
CBT BT1
분리된 비피도박테리움 롱굼 인판티스 CBT BT1은 실험에 사용된 모든 항생제에 대한 내성이 EFSA 항생제 내성기준 보다 낮게 나타났기 때문에 EFSA의 항생제에 대한 안정성 기준에 적합한 것으로 확인되었다. 비피도박테리아는 사이토크롬-매개 약물 수송 시스템의 결여로 카나마이신과 같은 아미니글리코사이드(aminiglycosides)에 대해서 내성이 있는 것으로 보고되었기 때문에, EFSA는 비피도박테리움에 대한 약제의 MIC 값을 요구하지 않는다. Isolated Bifidobacterium Ronggum Infante tooth BT1 CBT was identified because of resistance to any antibiotic used in the experiment appeared to be lower than EFSA antibiotic resistance criteria to be suitable for the stability criteria for the EFSA antibiotics. Since Bifidobacterium has been reported to be resistant to aminiglycosides such as kanamycin due to the lack of a cytochrome-mediated drug delivery system, EFSA does not require the MIC value of a drug for Bifidobacterium .
2) 장정착성 실험2) Fixation test
비피도박테리움 롱굼 인판티스 CBT BT1의 장 정착성 측정은 비피도박테리움 인판티스 T (ATCC 15697)를 대조군으로 하여 사람의 대장 상피세포에서 유래한 HT-29 세포주에서 실시하였다. HT-29 세포주에 각 균주들을 1시간 처리한 후 그람 염색과 생균수를 측정함으로써 균주들의 장 정착능을 비교하여 하기 표 5에 타내었다. Bifidobacterium Longong Infante tooth CBT Chapter fixability BT1 measurement was conducted at Bifidobacterium Infante tooth T by the HT-29 cell line derived (ATCC 15697) in a human colonic epithelial cells as a control. HT-29 cell lines treated with each strain for 1 hour, and then the number of viable cells and the number of viable cells were measured. The results are shown in Table 5 below.
장 정착성 측정 결과, 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 비피도박테리움 인판티스 T (ATCC 15697) 균주 보다 우수한 장 정착성을 보이는 균주임을 확인하였다. 이러한 결과는 본 발명의 상기 균주가 장 상피세포에 부착하여 장내 환경을 개선할 수 있음을 나타낸다. As a result of the measurement of the fixation property of the bifidobacterium Longong The infantis CBT BT1 strain is Bifidobacterium It was confirmed that the Infante Tees T (ATCC 15697) strain with a good fixing properties than the sheet strains. These results indicate that the strain of the present invention can improve the intestinal environment by adhering to the epithelial cells.
3) 용혈성 테스트3) Hemolytic test
용혈성 테스트(Hemolysis test)는 비피더스균이 인체 내에서 용혈성 독성이 없음을 확인하기 위한 것으로, 적혈구의 파괴 또는 분해되는 현상인 용혈성 여부를 검사하였다. Baumgartner 등의 방법에 의해서, 시험 균주를 5% 말 혈액이 보충된 MRS 배지에서 성장시키고 혐기성 조건 하에서 37도에서 48시간 동안 인큐베이션하였다. 균체 주위에 투명 환의 생성여부로 용혈성을 판단하였다. 본 발명의 균주의 용혈성 여부를 검사한 결과, 도 4를 통해서 확인되는 바와 같이, 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 말 혈액에 대해서 용혈성이 없어 인체에 무해한 것으로 확인되었다. The hemolysis test was conducted to confirm the absence of hemolytic toxicity in the human body of bifidobacteria. The hemolysis test was performed to determine whether hemolysis was caused by breakdown or degradation of red blood cells. By the method of Baumgartner et al., The test strain was grown in MRS medium supplemented with 5% horse blood and incubated at 37 ° C for 48 hours under anaerobic conditions. The hemolysis was judged by whether a transparent ring was formed around the cells. After a check for whether the hemolytic strains of the present invention, as will be confirmed through FIG. 4, Bifidobacterium ronggum Infante tooth BT1 CBT strain was found with respect to the end of the blood I do not have hemolytic harmless to the human body.
4) 급성독성실험4) Acute toxicity test
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주에 대한 안전성을 검증하기 위하여, 실험동물을 대상으로 급성독성실험을 실시하였다. 6주령의 암수 Sprague-Dawley (SD)계 쥐에게 본 발명의 동결 건조된 균주를 1.0 x 1011 cfu/kg로, 경구투여하였다. 대조군에는 0.85% 염수를 위내에 투여하였다. The Bifidobacterium Longong In order to verify the safety of the insecticide CBT BT1 strain, acute toxicity test was carried out on experimental animals. The lyophilized strain of the present invention was orally administered to a 6-week-old male Sprague-Dawley (SD) rats at 1.0 x 10 11 cfu / kg. The control group received 0.85% saline in the stomach.
모든 실험동물에 대한 임상 증상은 시료 투여 1일부터 부검일까지 1일 1회씩 14일간 관찰하였다. 관찰 결과는 하기 표 6에 나타내었다.Clinical symptoms for all experimental animals were observed for 1 day from
비피도박테리움 롱굼 인판티스 CBT BT1 균주를 투여한 후, 모든 대조군 및 투여군에서 폐사율을 관찰할 수 없었으며, 또한 특이적인 임상증상을 나타내는 개체를 발견할 수 없었다. 또한 투여 후 14일간 먹이와 물의 섭취량, 및 체온을 관찰한 결과, 투여군과 대조군 사이에 통계학적으로 유의적인 차이를 발견할 수 없었다. After administration of Bifidobacterium longum infantis CBT BT1 strain, mortality was not observed in all the control and administration groups, and no individual showing any specific clinical symptoms could be found. In addition, food, water intake, and body temperature were observed for 14 days after administration, and no statistically significant difference was found between the administration group and the control group.
cfu/kg> 10 11
cfu /
cfu/kg> 10 11
cfu /
실시예 2. 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 유전학적 분석Example 2. Genetic analysis of Bifidobacterium longum infantis CBT BT1 strain
비피도박테리움 롱굼 인판티스 CBT BT1 (KCTC 11859BP) 균주의 지놈 시퀀싱은 PacBio RS II System (DNA Link, Republic of Korea)을 이용하여 행하였다. 지놈에 대해서, 10 kb 도서관을 만들고, C2-P4 chemistry를 가지는 SMRTcell 중 하나를 이용하여 지놈 시퀀싱을 실시하였다. 지놈 시퀀싱에 의해서 337,655,282 bp의 긴 서열이 수득되었다. SMRTpipe HGAP에 의해 De novo 조립을 실시하고, SMRTpipe AHA에 의해서 스캐폴딩과 갭 필링을 행하였다. 구조 유전자 예측은 Glimmer3로 하였고, 유전자 annotation은 Pfam, Uniref100, KEGG, COG 및 GenBank NR 데이터베이스에 대해서 BLASTP에 의해서 얻은 결과를 이용하여 AutoFACT (Koski et al. 2005)에 의해서 행하였다. Transfer RNA 및 리보좀 RNA는 각각 tRNAscan-SE (Lowe and Eddy 1997) 및 RNAmmer (Lagesen et al. 2007)를 이용하여 행하였다. Clusters of Orthologous Groups (COGs) category에 의한 유전자의 기능적 분류는 e-value cutoff를 1e-2 미만으로 하여 RPS-BLAST를 이용하여 행하였다(Mavromatis et al. 2009). Genomic sequencing of the Bifidobacterium longum infantis CBT BT1 (KCTC 11859BP) strain was performed using PacBio RS II System (DNA Link, Republic of Korea). For the genome, a 10 kb library was created and genomic sequencing was performed using one of the SMRTcells with C2-P4 chemistry. A long sequence of 337,655,282 bp was obtained by genomic sequencing. De novo assembly was performed by SMRTpipe HGAP, and scaffolding and gap filling were performed by SMRTpipe AHA. Structural gene prediction was performed by Glimmer3 and gene annotation was performed by AutoFACT (Koski et al. 2005) using the results obtained by BLASTP for Pfam, Uniref100, KEGG, COG and GenBank NR databases. Transfer RNA and ribosomal RNA were performed using tRNAscan-SE (Lowe and Eddy 1997) and RNAmmer (Lagesen et al. 2007), respectively. Functional classification of genes by the Clusters of Orthologous Groups (COGs) category was performed using RPS-BLAST (Mavromatis et al. 2009) with e-value cutoffs less than 1e-2.
지놈 상의, 특수한 유전자의 존재는 수집된 데이터세트에 대해서 서열 상동성 ≥ 50%의 파라미터로 BLASTP를 이용하여 행하였다. 지놈의 대사 경로 분석은 KEGG automatic annotation server를 이용해서 행하였다 (Moriya et al. 2007). 2차 대사산물 생합성 유전자 분석은 antiSMASH version 3.0.0 (Blin et al. 2013; Blin et al. 2014) (http://antismash.secondarymetabolites.org/)을 이용해서 행하였다 .The presence of a specific gene on the genome was performed using BLASTP as a parameter of sequence homology ≥ 50% for the collected data sets. Analysis of the genome pathway was performed using the KEGG automatic annotation server (Moriya et al. 2007). Genetic analysis of secondary metabolite biosynthesis was performed using antiSMASH version 3.0.0 (Blin et al., 2013; Blin et al., 2014) ( http://antismash.secondarymetabolites.org/ ).
2-1. HMO (Human Milk Oligosaccharide) 대사 관련 유전자2-1. HMO (Human Milk Oligosaccharide) Metabolism Related Genes
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈의 유전자 컨텐츠 분석 결과, 모유 올리고당 대사 관련 유전자 가운데 α-만노시다아제, β-만노시다아제, 엔도-β-N-아세틸글루코사미니다아제, 엔도-α-N-아세틸갈락토사미니다아제, 시알리다아제, α-푸코시다아제, α-N-아세틸글루코사미니다아제, β-N-아세틸글루코사미니다아제, 및 β-N-아세틸헥소사미니다아제를 코드화하는 유전자를 포함하는 것으로 확인되었다. 이로써 본 발명의 균주가 인간 효소에 의해서 소화되지 않는 모유 올리고당을 소화시켜 공급할 수 있다는 것을 알 수 있다. As a result of analyzing the genomic contents of the genome of Bifidobacterium longum infantis CBT BT1 strain of the present invention, it was found that the genes related to the metabolism of breast milk oligosaccharide were α - mannosidase, β - mannosidase, endo - β - N - acetylglucosaminidase endo - α - N - The Lactobacillus Sami go acetyl kinase, sialidase, α - Foucault let kinase, α - N - acetyl glucosyl Sami The kinase, β - N - acetyl glucosyl Sami The kinase, and β - N - acetyl It was confirmed to contain a gene coding for hexosaminidase. Thus, it can be seen that the strain of the present invention can digest and supply the milk oligosaccharide which is not digested by the human enzyme.
2-2. 비타민 생합성 유전자2-2. Vitamin biosynthesis gene
유전자 분석 결과, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 비타민, 특히 비타민 B 군의 생합성을 위한 모든 유전자를 갖는 것으로 확인되었다. 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈에는 세 종류의 비타민을 합성할 수 있는 유전자가 존재한다. 구아노신5'-트리포스페이트 (GTP)로부터 폴레이트를 합성하고, 코리스메이트로부터 폴레이트(B2)를 합성하고, L-아스파테이트로부터 니코틴산(B3)을 합성하며, D-리불로스 5-포스페이트 및 GTP로부터 리보플라빈(B2)을 합성하는 유전자를 갖는 것으로 확인되었다. As a result of gene analysis, Bifidobacterium Longong It was confirmed that the intactis CBT BT1 strain has all the genes for the biosynthesis of vitamins, particularly the vitamin B group. In the genome of the Bifidobacterium longum infantis CBT BT1 strain of the present invention, there exists a gene capable of synthesizing three kinds of vitamins. Synthesis of folate from guanosine 5'-triphosphate (GTP), synthesis of folate (B2) from cholestate, synthesis of nicotinic acid (B3) from L-aspartate, synthesis of D- It has been confirmed that it has a gene for synthesizing riboflavin (B2) from GTP.
2-3. 우레아 이송 시스템 2-3. Urea transfer system
비피도박테리움 롱굼 인판티스 CBT BT1 균주에 대한 종 특이적 유전자 분석 결과, 우레아제 단백질을 코드화하는 ure 유전자 및 우레아 이송 단백질을 코드화하는 urt 유전자를 갖는 것으로 확인되었다. 이러한 유전자는 다른 비피도박테리움속 균주에는 발견되지 않는 것으로, 본 발명의 균주가 다른 균주들에 비해 영양분을 더 효율적으로 이용가능하고, 질소원의 리사이클링에 관여한다는 것을 시사한다. Bifidobacterium Longong Species-specific gene analysis of the CBT Infante tooth BT1 strain, ure encoding a urease protein And the urt gene encoding the urea transfer protein. These genes are not found in other strains of Bifidobacterium sp., Suggesting that the strains of the present invention are more efficiently available for nutrients than other strains and are involved in the recycling of nitrogen sources.
도 7에서, 흑색 및 황색 화살표는 각각 우레아 이송 단백질 및 우레아제를 코드화하는 유전자를 나타내고, 회색 화살표로 표시되는 유전자는 니켈-수송 단백질을 코드화 한다. 화살표 상의 숫자는 유전자 위치 택 번호이고, 유전자 사이의 숫자는 ATCC 15697 및 BT1 균주들 간의 urtA(우레아 수송 시스템 기질-결합 단백질); urtB 및 urtC (우레아 수송 시스템 퍼미아제 단백질); urtD 및 urtE (우레아 수송 시스템 ATP-결합 단백질); ureAB (우레아 서브유니트 감마/베타); ureC (우레아제 서브유니트 알파); ureE, ureF, ureG, 및 ureD (우레아제 악세사리 단백질) 의 아미노산 서열 상동성을 나타낸다. In Figure 7, the black and yellow arrows indicate the genes encoding the urea transfer protein and urease, respectively, and the gene labeled with the gray arrow codes the nickel-transport protein. The numbers on the arrow are the gene locator numbers, the numbers between the genes are urtA (urea transport system substrate-binding protein) between
2-4. 유해 세균의 성장 억제2-4. Suppress growth of harmful bacteria
본 발명의 균주의 항균제의 생성에 의해서 유해균의 생장을 억제하는 효과를 확인하기 위하여, 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈 상에서 2차대사산물 생합성 및 항생제 생산과 관련된 유전자의 존재 여부를 분석하였다. In order to confirm the effect of inhibiting the growth of harmful microorganisms by the production of the antimicrobial agent of the strain of the present invention, Bifidobacterium Longong Infante tooth for the presence of the gene were related to the biosynthesis of secondary metabolites and antibiotic production on the genome of strain CBT BT1.
도 8을 참조하면, 2차 대사산물 생합성 조사 결과, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 2종류 이상의 박테리오신을 코드화하는 유전자를 포함하고, 렌티바이오틱스를 코드화하는 렌티펩타이드 유전자를 포함하는 것으로 확인되었다. 도 8에 도시된 바와 같이, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주는 박테리오신, 렌티펩타이드, 및 비-리보좀 펩타이드(non-ribosomal peptides) 및 폴리케타이드의 생합성을 위한 단백질을 코드화하는 유전자를 갖는다. 본 발명의 균주는 박테리오신-코드화 유전자, 페나진(phenazine) 생합성을 위한 단백질을 코드화하는 유전자, 폴리케타이드 및 비-리보좀 펩타이드를 코드화하는 유전자를 갖는 것으로 확인되었다. 이러한 결과를 볼 때, 본 발명의 비피도박테 리움 롱굼 인판티스 CBT BT1 균주는 박테리오신과 같은 항균화합물의 생산에 의해서 병원균의 증식을 억제할 수 있다는 것을 알 수 있다. Referring to FIG. 8, as a result of the secondary metabolite biosynthesis, the Bifidobacterium longum infection typhimurium CBT BT1 strain of the present invention contains a gene encoding two or more bacteriocins, and a lentiprotein gene encoding lentiviotics . As shown in Figure 8, the Bifidobacterium longum infantis CBT BT1 strain of the present invention encodes a protein for biosynthesis of bacteriocins, lentipeptides , and non-ribosomal peptides and polyketides Gene. The strains of the present invention were found to have a bacteriocin-encoding gene, a gene encoding a protein for phenazine biosynthesis, a gene encoding a polyketide and a non-ribosomal peptide. From these results, it can be seen that the Bifidobacterium longum infantis CBT BT1 strain of the present invention can inhibit the growth of pathogenic bacteria by the production of an antibacterial compound such as bacteriocin.
2-5. 병원성 유전자의 부재2-5. Absence of pathogenic genes
PAIs (Pathogenicity islands) 및 REIs(Antimicrobial resistance islands)에 대한 분석은 PAI 데이터베이스 (Yoon et al. 2007; Yoon et al. 2015)의 PAI finder를 이용하여 행하였다. 분석 결과, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 지놈에는 PAI (Pathogenicity islands) 및 PAI-유사 영역은 존재하지 않는 것으로 확인되었다. PAIs (Pathogenicity islands) and REIs (Antimicrobial resistance islands) were analyzed using the PAI database of the PAI database (Yoon et al. 2007; Yoon et al. As a result of the analysis, the Bifidobacterium Longong It was found that no pathogenicity islands (PAIs) and no PAI-like regions were present in the genome of the intactis CBT BT1 strain.
실시예 3. 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 성장 촉진 효과Example 3: Growth promoting effect of Bifidobacterium longum infantis CBT BT1 strain
이하 실시예에서 본 발명의 균주의 특성과 성장촉진용 효능을 입증한다. 모든 실시예의 실험 결과는 평균(mean)ㅁ표준편차(SD)로 표시하였고, 실험 결과의 통계처리는 GraphPad PrismTM 6.0을 이용하였으며 실험군 간 평균의 차이는 one-way ANOVA로 유의성을 확인한 후 Tukey's multiple range test를 이용하여 사후 검증하였다. The following examples demonstrate the characteristics of the strain of the present invention and the efficacy for growth promotion. The experimental results of all the examples were expressed as mean (SD) and the statistical analysis of the experimental results was performed using GraphPad Prism TM 6.0. The mean difference between the experimental groups was determined by one-way ANOVA and then Tukey's multiple range test.
3-1. 본 발명의 균주의 배양물 및 그를 포함하는 조성물의 제조3-1. The culture of the strain of the invention and the preparation of a composition comprising it
비피도박테리움 롱굼 인판티스 CBT BT1 균주(KCTC 11859BP)를 BL 브로스(BD Diagnostics, Sparks, MD)에서 24시간 37℃에서 배양하였고, 인산염 버퍼 용액(PBS, 10mM 인산나트륨, 130mM 염화나트륨, pH 7.4)에 1011 CFU/ml로 희석하여 초음파처리 후, 상청액을 원심 분리하여 0.45 ㎛ 포어 사이즈의 필터로 여과하고, 동결 건조한 후 -20℃에 생체내 실험 전까지 보관하였다. Bifidobacterium Longong 10 to Infante tooth CBT BT1 strain (KCTC 11859BP) to BL broth was cultured for 24 hours 37 ℃ in (BD Diagnostics, Sparks, MD) , a phosphate buffer solution (PBS, 10mM sodium phosphate, 130mM sodium chloride, pH 7.4) 11 CFU / ml. After the supernatant was centrifuged, the supernatant was filtered through a 0.45 μm pore size filter, lyophilized, and stored at -20 ° C. until in vivo experiment.
3-2. 비만 동물 모델 및 샘플링3-2. Obese animal models and sampling
동물실험은 Institutional Animal Care and Use Committee (IACUC)의 Animal use and Care Protocol을 준수하여 진행하였다. 실험동물은 ㈜새론바이오 (Uiwang, Korea)에서 수컷 SD 실험용 쥐 6주령을 (그룹당 10 마리, 암컷 5마리, 수컷 5마리) 구입하여 24시간 동안 적응기간을 가진 후, 17일간 사육이 진행되었고, 사육환경은 24ㅁ2℃, 습도 55ㅁ15%에서 light cycle이 12시간 유지되었다. 기초 식이를 위해 17일간 보리 성분의 사료 (barley feed, A04, UAR, Vilemoisson- sur-Orge, France)를 섭취하도록 하였으며, 음용수는 자유롭게 섭취하거나 비피도박테리움 롱굼 인판티스 CBT BT1(107 CFU/head/day)를 음용수에 섞어 섭취하도록 하였다. Animal experiments were conducted in accordance with the Animal Use and Care Protocol of the Institutional Animal Care and Use Committee (IACUC). Male animals were sacrificed at 6 weeks of age (10 dogs per group, 5 females, 5 males) in a male SD rats in Uiwang, Korea for 24 hours and then maintained for 17 days. The incubation environment was maintained for 12 hours at 24 ㅁ 2 ℃ and humidity 55 ㅁ 15%. For the basic diets, barley feed (A04, UAR, Vilemoisson-sur-Orge, France) was consumed for 17 days. Drinking water was either consumed freely or Bifidobacterium longum infantis CBT BT1 (10 7 CFU / head / day) were mixed with drinking water.
3-3 본 발명의 균주의 성장발육 촉진 효과 3-3 Growth Development Promotion Effect of the Strain of the Present Invention
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 성장 촉진 효능을 관찰하기 위해, 실험 시작 후 17일까지 매일 체중과 섭취한 음용수 및 사료의 양을 측정하였다. 체중의 증가는 실험 날짜의 체중에서 실험 시작 날짜의 체중을 빼서 계산하였다. 음용수와 사료는 케이지 별 측정 후, 마리당 계산하여 17일까지의 총 양을 계산하였다. 체중증가의 효율은 총 섭취한 사료의 양에서 증가한 체중을 나누어 계산하였다.In order to observe the growth promoting effect of the Bifidobacterium longum infantis CBT BT1 strain of the present invention, the daily weight and the amount of the drinking water and feed consumed were measured until the 17th day after the start of the experiment. The increase in body weight was calculated by subtracting the body weight of the experiment from the beginning of the experiment. The total amount of drinking water and feed for each cage was calculated and calculated to 17 days. The efficiency of weight gain was calculated by dividing the body weight gain by the total amount of feed consumed.
본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 마우스 성장 촉진 효과를 관찰하기 위해, 보리 성분의 사료를 17일 동안 먹여 기초식이를 유도하였다. 비피도박테리움 롱굼 인판티스 CBT BT1을 음용수에 섞어 먹인 그룹(BT1)의 경우, 일반 음용수를 정상적으로 먹인 그룹(NC)에 비해 12일부터 유의성 있게 체중이 증가하는 것을 관찰하였다 (12day; p<0.05, 13 to 17 days; p<0.01) (도 9a). 그러나 17일 동안 섭취한 총 사료의 섭취량(FI)과 음용수의 양(WI)은 두 그룹간 특별한 차이를 보이지 않았다(도 9b). 본 발명의 균주의 투여가 사료 섭취에 영향을 미치지 않았고, 체중(WG)의 증가가 사료 섭취량(FI)의 차이에 기인하지 않았음을 확인할 수 있다. 이와 같이 섭취한 사료의 양 대비 체중증가의 효율(FI/WG)은, 정상 그룹에 대비하여 비피도박테리움 롱굼 인판티스 CBT BT1을 섭취한 그룹에서 유의미한 결과가 나타나, 본 발명의 비피도박테리움 롱굼 인판티스 CBT BT1 균주의 투여에 의해 성장이 촉진되는 것이 확인되었다. The Bifidobacterium Longong In order to observe the mouse growth promoting effect of the infantis CBT BT1 strain, a diet of barley was fed for 17 days to induce a basic diet. Bifidobacterium longum insipidus CBT BT1 group (BT1) mixed with drinking water showed significant increase in body weight from 12th day compared to normal drinking group (12day; p <0.05 , 13 to 17 days; p < 0.01) (Fig. 9A). However, the intake of total feed (FI) and the amount of drinking water (WI) consumed for 17 days did not show any particular difference between the two groups (Fig. 9b). It can be confirmed that the administration of the strain of the present invention did not affect the feed intake and that the increase in the body weight (WG) was not caused by the difference in the feed intake amount FI. Efficiency (FI / WG) of increased amount compared to the weight so the feed intake, the Bifidobacterium in preparation for the normal group Longong It shows the significant results from the ingestion of Infante Tees CBT BT1 group, Bifidobacterium of the present invention Leeum Longong Infante tooth that has been confirmed that growth is promoted by the administration of CBT BT1 strain.
이상에서 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위 내에서 다양하게 변형 또는 변경된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 따라서 본 발명의 진정한 보호범위는 전술한 실시예가 아니라 이하의 특허청구범위 및 그와 균등한 범위로 해석되어야 할 것이다.The preferred embodiments of the present invention have been described above. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Accordingly, the true scope of protection of the present invention is not limited to the above-described embodiments, but should be interpreted within the scope of the following claims and equivalents thereof.
Claims (7)
BFID ( Bifidobacterium longum bv. Infantis CBT BT1) deposited with the Korean Collection for Type Culture (KCTC) under accession number KCTC 11859BP. Bifidobacterium longum bv. Infantis CBT BT1 Bovine oligosaccharides containing bifidobacteria A functional food composition which helps human growth by promoting digestion .
The method of claim 1, wherein the bifidobacterium has a gene for degrading the mammary oligosaccharide, and the gene for degrading the mammary oligosaccharide is β -galactosidase, α -mannosidase, endo- β - N- And a gene coding for α - fucosidase. The functional food composition according to any one of claims 1 to 4, wherein the functional food composition is a composition for promoting digestion of human milk oligosaccharide .
The method of claim 1, wherein the Bifidobacterium is functional to assist the riboflavin (B2), niacin (B3), and folate (B9) human growth by the digestion of breast milk oligosaccharides comprising the biosynthesis gene Food composition .
The functional food composition according to claim 1, wherein the bifidus bacterium has a ure gene encoding a urease and a urt gene encoding a urea transfer protein. The functional food composition assists human growth by promoting digestion of milk oligosaccharide .
The Bifidobacterium ronggum Infante tooth BT1 CBT (Bifidobacterium longum bv. Infantis CBT BT1) digestion and animal body weight gain Feed composition of the breast milk oligosaccharides, including the strain of (KCTC 11859BP) according to claim 1.
The method of claim 1 wherein the food composition comprises Bifidobacterium ronggum Infante tooth CBT BT1: breast milk oligosaccharides comprising the live cells or dried bacteria (accession No. KCTC 11859BP) strain 10 8 to 10 12 cfu / g A functional food composition which helps human growth by promoting digestion .
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150071119A KR101589464B1 (en) | 2015-05-21 | 2015-05-21 | New bifidobacterium strain and nutraceutical composition for improving growth comprising the same |
PCT/KR2015/007225 WO2016186243A1 (en) | 2015-05-21 | 2015-07-13 | Novel bifidobacterium strain and functional food composition containing same for promoting growth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150071119A KR101589464B1 (en) | 2015-05-21 | 2015-05-21 | New bifidobacterium strain and nutraceutical composition for improving growth comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101589464B1 true KR101589464B1 (en) | 2016-02-01 |
Family
ID=55354115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150071119A KR101589464B1 (en) | 2015-05-21 | 2015-05-21 | New bifidobacterium strain and nutraceutical composition for improving growth comprising the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101589464B1 (en) |
WO (1) | WO2016186243A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101975031B1 (en) | 2019-04-02 | 2019-05-07 | (주)에이투젠 | Novel Bifidobacterium longum ATG-F5, and cosmetics composition comprising thereof |
KR102164198B1 (en) * | 2020-01-16 | 2020-10-12 | 한국생명공학연구원 | Bifidobacterium longum subsp. infantis IN02 and Food composition comprising thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108064132A (en) | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | The method and composition related with the antimicrobial treatments of illness and diagnosis |
CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
CN114574391B (en) * | 2022-03-11 | 2022-10-21 | 南昌恒赋健康管理有限公司 | Microbial inoculum for promoting growth and improving immunity and application thereof in formula milk powder |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100472865B1 (en) * | 2002-08-28 | 2005-03-10 | (주) 피엘바이오 | Korean Isolate Bifidobacterium infantis PL9506 with High Nutraceutical Activity |
KR100530211B1 (en) | 2003-12-29 | 2005-11-22 | 양순길 | Healthy and functional food composition for the improvement of the studying capability and its process |
KR100561286B1 (en) | 2004-05-19 | 2006-03-15 | 일양약품주식회사 | Growth-promoting Composition Comprising Dried Yeast, Extracted Natural Substances and Nutrient Mixed Powder |
KR100865363B1 (en) * | 2002-09-16 | 2008-10-24 | 매일유업주식회사 | Bifidobacterium infantis MAEIL-K9 strain and health-promoting food containing the same |
KR100887377B1 (en) | 2007-03-09 | 2009-03-05 | 김재현 | Nutraceutical for children and teenagers |
-
2015
- 2015-05-21 KR KR1020150071119A patent/KR101589464B1/en active IP Right Grant
- 2015-07-13 WO PCT/KR2015/007225 patent/WO2016186243A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100472865B1 (en) * | 2002-08-28 | 2005-03-10 | (주) 피엘바이오 | Korean Isolate Bifidobacterium infantis PL9506 with High Nutraceutical Activity |
KR100865363B1 (en) * | 2002-09-16 | 2008-10-24 | 매일유업주식회사 | Bifidobacterium infantis MAEIL-K9 strain and health-promoting food containing the same |
KR100530211B1 (en) | 2003-12-29 | 2005-11-22 | 양순길 | Healthy and functional food composition for the improvement of the studying capability and its process |
KR100561286B1 (en) | 2004-05-19 | 2006-03-15 | 일양약품주식회사 | Growth-promoting Composition Comprising Dried Yeast, Extracted Natural Substances and Nutrient Mixed Powder |
KR100887377B1 (en) | 2007-03-09 | 2009-03-05 | 김재현 | Nutraceutical for children and teenagers |
Non-Patent Citations (3)
Title |
---|
http://www.nias.go.kr/front/prboardView.nias?cmCode=M090814151125016&boardSeqNum=25&columnName=&searchStr=&currPage=47(2009.12.02.)* * |
http://www.nias.go.kr/front/prboardView.nias?cmCode=M090814151125016&boardSeqNum=25&columnName=&searchStr=&currPage=47(2009.12.02.)* |
Korean Journal of Microbiology, Vol.49, pp.275-281(2013.)* * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101975031B1 (en) | 2019-04-02 | 2019-05-07 | (주)에이투젠 | Novel Bifidobacterium longum ATG-F5, and cosmetics composition comprising thereof |
WO2020204260A1 (en) * | 2019-04-02 | 2020-10-08 | (주) 에이투젠 | Novel bifidobacterium longum strain or cosmetic composition comprising same |
KR102164198B1 (en) * | 2020-01-16 | 2020-10-12 | 한국생명공학연구원 | Bifidobacterium longum subsp. infantis IN02 and Food composition comprising thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2016186243A1 (en) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101589466B1 (en) | Use of bifidobacterium longum cbt bg7 strain for promoting growth and nutraceutical composition for promoting growth comprising the same | |
KR101589465B1 (en) | Use of bifidobacterium breve cbt br3 strain for promoting growth and nutraceutical composition for promoting growth comprising the same | |
ES2695149T3 (en) | Bacillus strains sensitive to antibiotics that have an antimicrobial effect against E. coli and Clostridium perfringens and that have a high capacity for sporulation | |
KR101589464B1 (en) | New bifidobacterium strain and nutraceutical composition for improving growth comprising the same | |
KR20140037544A (en) | Composition for preventing or treating irritable bowel syndrome | |
US8728461B2 (en) | Lactic acid bacterium having high immunoglobulin-A-inducing ability | |
KR102024883B1 (en) | Lactobacillus Fermentum KBL 375 and Use Thereof | |
CN103750341A (en) | Inactivated bacteroid micro-ecological preparation and preparation method thereof | |
KR101473146B1 (en) | Composition for preventing or treating irritable bowel syndrome | |
US10098916B2 (en) | Strains of the genus Lactobacillus and use thereof | |
KR100868777B1 (en) | Food composition with Bifidobacterium adolescentis to utilize RS-3 type resistant starch | |
KR100803532B1 (en) | - DF20KCTC10942BP Lactobacillus salivarius sp. salivarius DF20 having been Acid-tolerant Bile-tolerant Antibacterial activity and possesed Alpha-galactosidase | |
KR101453982B1 (en) | Composition for preventing or treating irritable bowel syndrome | |
KR101473147B1 (en) | Composition for preventing or treating irritable bowel syndrome | |
KR101589467B1 (en) | Use of bifidobacterium bifidum cbt bf3 strain for promoting growth and nutraceutical composition for promoting growth comprising the same | |
KR101726207B1 (en) | --glucosidase LT19-2 [KCTC18497P]Novel Bifidobacterium animalis LT19-2 strain[KCTC18497P] having excellent -glucosidase activity | |
KR101453984B1 (en) | Composition for preventing or treating irritable bowel syndrome | |
KR100930251B1 (en) | Bifidobacterium longum having the ability of reducing cholesterol in blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190117 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20200113 Year of fee payment: 5 |